全文获取类型
收费全文 | 48797篇 |
免费 | 3570篇 |
国内免费 | 2468篇 |
专业分类
耳鼻咽喉 | 254篇 |
儿科学 | 1358篇 |
妇产科学 | 472篇 |
基础医学 | 11232篇 |
口腔科学 | 387篇 |
临床医学 | 3658篇 |
内科学 | 13532篇 |
皮肤病学 | 578篇 |
神经病学 | 1215篇 |
特种医学 | 620篇 |
外国民族医学 | 7篇 |
外科学 | 2106篇 |
综合类 | 6299篇 |
现状与发展 | 18篇 |
预防医学 | 7323篇 |
眼科学 | 385篇 |
药学 | 2466篇 |
13篇 | |
中国医学 | 852篇 |
肿瘤学 | 2060篇 |
出版年
2024年 | 47篇 |
2023年 | 611篇 |
2022年 | 1860篇 |
2021年 | 2149篇 |
2020年 | 1694篇 |
2019年 | 1477篇 |
2018年 | 1492篇 |
2017年 | 1466篇 |
2016年 | 1732篇 |
2015年 | 2033篇 |
2014年 | 2820篇 |
2013年 | 2991篇 |
2012年 | 2756篇 |
2011年 | 3235篇 |
2010年 | 2685篇 |
2009年 | 2438篇 |
2008年 | 2391篇 |
2007年 | 2527篇 |
2006年 | 2269篇 |
2005年 | 1997篇 |
2004年 | 1761篇 |
2003年 | 1534篇 |
2002年 | 1222篇 |
2001年 | 1185篇 |
2000年 | 961篇 |
1999年 | 861篇 |
1998年 | 754篇 |
1997年 | 770篇 |
1996年 | 627篇 |
1995年 | 631篇 |
1994年 | 594篇 |
1993年 | 473篇 |
1992年 | 354篇 |
1991年 | 302篇 |
1990年 | 269篇 |
1989年 | 244篇 |
1988年 | 231篇 |
1987年 | 167篇 |
1986年 | 142篇 |
1985年 | 287篇 |
1984年 | 180篇 |
1983年 | 134篇 |
1982年 | 120篇 |
1981年 | 98篇 |
1980年 | 68篇 |
1979年 | 58篇 |
1978年 | 51篇 |
1977年 | 31篇 |
1976年 | 31篇 |
1975年 | 6篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
11.
12.
13.
14.
《Saudi Pharmaceutical Journal》2020,28(10):1243-1252
The novel coronavirus outbreak has reported to be rapidly spreading across the countries and becomes a foremost community health alarm. At present, no vaccine or specific drug is on hand for the treatment of this infectious disease. This review investigates the drugs, which are being evaluated and found to be effective against nCOVID-19 infection. A thorough literature search was performedon the recently published research papers in between January 2020 to May 2020, through various databases like “Science Direct”, “Google Scholar”, “PubMed”,“Medline”, “Web of Science”, and “World Health Organization (WHO)”. We reviewed and documented the information related with the current and future aspects for the management and cure of COVID-19. As of 21st July 2020 a total of 14,562,550 confirmed cases of coronavirus and 607,781 deaths have been reported world-wide. The main clinical feature of COVID-19 ranges from asymptomatic disease to mild lower respiratory tract illness to severe pneumonia, acute lung injury, acute respiratory distress syndrome (ARDS), multiple organ dysfunction, and death. The drugs at present used in COVID-19 patients and ongoing clinical trials focusing on drug repurposing of various therapeutic classes of drug e.g. antiviral, anti-inflammatory and/or immunomodulatory drugs along with adjuvant/supportive care. Many drugs on clinical trials shows effective results on preliminary scale and now used currently in patients. Adjuvant/supportive care therapy are used in patients to get the best results in order to minimize the short and long-term complications. However, further studies and clinical trials are needed on large scale of population to reach any firm conclusion in terms of its efficacy and safety. 相似文献
15.
16.
Auda A. Eltahla Fabio Luciani Peter A. White Andrew R. Lloyd Rowena A. Bull 《Viruses》2015,7(10):5206-5224
The hepatitis C virus (HCV) is a pandemic human pathogen posing a substantial health and economic burden in both developing and developed countries. Controlling the spread of HCV through behavioural prevention strategies has met with limited success and vaccine development remains slow. The development of antiviral therapeutic agents has also been challenging, primarily due to the lack of efficient cell culture and animal models for all HCV genotypes, as well as the large genetic diversity between HCV strains. On the other hand, the use of interferon-α-based treatments in combination with the guanosine analogue, ribavirin, achieved limited success, and widespread use of these therapies has been hampered by prevalent side effects. For more than a decade, the HCV RNA-dependent RNA polymerase (RdRp) has been targeted for antiviral development. Direct acting antivirals (DAA) have been identified which bind to one of at least six RdRp inhibitor-binding sites, and are now becoming a mainstay of highly effective and well tolerated antiviral treatment for HCV infection. Here we review the different classes of RdRp inhibitors and their mode of action against HCV. Furthermore, the mechanism of antiviral resistance to each class is described, including naturally occurring resistance-associated variants (RAVs) in different viral strains and genotypes. Finally, we review the impact of these RAVs on treatment outcomes with the newly developed regimens. 相似文献
17.
《Vaccine》2016,34(8):1115-1125
Chronic hepatitis C virus (HCV) infection represents a major health threat to global population. In India, approximately 15–20% of cases of chronic liver diseases are caused by HCV infection. Although, new drug treatments hold great promise for HCV eradication in infected individuals, the treatments are highly expensive. A vaccine for preventing or treating HCV infection would be of great value, particularly in developing countries. Several preclinical trials of virus-like particle (VLP) based vaccine strategies are in progress throughout the world. Previously, using baculovirus based system, we have reported the production of hepatitis C virus-like particles (HCV-LPs) encoding structural proteins for genotype 3a, which is prevalent in India. In the present study, we have generated HCV-LPs using adenovirus based system and tried different immunization strategies by using combinations of both kinds of HCV-LPs with other genotype 3a-based immunogens. HCV-LPs and peptides based ELISAs were used to evaluate antibody responses generated by these combinations. Cell-mediated immune responses were measured by using T-cell proliferation assay and intracellular cytokine staining. We observed that administration of recombinant adenoviruses expressing HCV structural proteins as final booster enhances both antibody as well as T-cell responses. Additionally, reduction of binding of VLP and JFH1 virus to human hepatocellular carcinoma cells demonstrated the presence of neutralizing antibodies in immunized sera. Taken together, our results suggest that the combined regimen of VLP followed by recombinant adenovirus could more effectively inhibit HCV infection, endorsing the novel vaccine strategy. 相似文献
18.
丙型肝炎病毒(HCV)感染在慢性肾功能不全患者中较常见,尤其是在进行透析的患者中,HCV感染较普通患者的风险极大增加,同时还会导致肝细胞癌及肝硬化的发病率明显升高。近年来直接抗病毒药物(DAAs)在慢性丙型肝炎的治疗中取得了较好的疗效及安全性,本文通过总结DAAs在丙型肝炎合并透析患者中的应用进展,发现对于基因1~6型HCV合并透析患者,推荐使用G/P方案;由于索磷布韦(SOF)经肾脏代谢,在重度肾损害人群中的血药浓度较高,因此SOF组合方案并不推荐用于丙型肝炎合并透析患者的治疗。 相似文献
19.
Comparative safety study on severe anemia by simeprevir versus telaprevir‐based triple therapy for chronic hepatitis C 下载免费PDF全文
Eiichi Ogawa Norihiro Furusyo Eiji Kajiwara Hideyuki Nomura Akira Kawano Kazuhiro Takahashi Kazufumi Dohmen Takeaki Satoh Koichi Azuma Makoto Nakamuta Toshimasa Koyanagi Kazuhiro Kotoh Shinji Shimoda Jun Hayashi The Kyushu University Liver Disease Study Group 《Journal of gastroenterology and hepatology》2015,30(8):1309-1316
20.
《Vaccine》2020,38(39):6141-6152
Influenza vaccination is considered the most valuable means to prevent and control seasonal influenza infections, which causes various clinical symptoms, ranging from mild cough and fever to even death. Among various influenza vaccine types, the inactivated subunit type is known to provide improved safety with reduced reactogenicity. However, there are some drawbacks associated with inactivated subunit type vaccines, with the main ones being its low immunogenicity and the induction of Th2-biased immune responses. In this study, we investigated the role of a single-stranded RNA (ssRNA) derived from the intergenic region in the internal ribosome entry site of the Cricket paralysis virus as an adjuvant rather than the universal vaccine for a seasonal inactivated subunit influenza vaccine. The ssRNA adjuvant stimulated not only well-balanced cellular (indicated by IgG2a, IFN-γ, IL-2, and TNF-α) and humoral (indicated by IgG1 and IL-4) immune responses but also a mucosal immune response (indicated by IgA), a key protector against respiratory virus infections. It also increases the HI titer, the surrogate marker of influenza vaccine efficacy. Furthermore, ssRNA adjuvant confers cross-protective immune responses against heterologous influenza virus infection while promoting enhanced viral clearance. Moreover, ssRNA adjuvant increases the number of memory CD4+ and CD8+ T cells, which can be expected to induce long-term immune responses. Therefore, this ssRNA-adjuvanted seasonal inactivated subunit influenza vaccine might be the best influenza vaccine generating robust humoral and cellular immune responses and conferring cross-protective and long-term immunity. 相似文献